Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) Strong Price Momentum Continues

[[tagnumber 0]]Shares of Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) keep climbing outside of the trading range this week. Though the current rally already resulted in a new 52–week high, it looks like the stock could reach even higher levels The company just recently issued warrants that will dilute shareholders while its financials also provide no base for stock growth.[[tagnumber 1]] [[tagnumber 0]][[tagnumber 3]][[tagnumber 1]] [[tagnumber 0]]Yesterday, NAVB closed the market with a small 2.63% gain at $2.34 for a share while the trading volume dropped down, which could be a signal for reversal later this week. On the other hand, the major technical indicators are still in a bullish position, implying NAVB could gain some more value today.[[tagnumber 1]] [[tagnumber 0]] [[tagnumber 1]] [[tagnumber 0]]Though NAVB recently announced the winning of a new $1.8 million grant from the National Cancer Institute, its financial reports show that it will not be enough for the company to make a profit. NAVB balance sheet shows already heavy debts that are supposed to be dilutive for shareholders on the long–term.[[tagnumber 1]] [[tagnumber 0]] [[tagnumber 12]][[tagnumber 1]] [[tagnumber 0]]In May this year, a new term loan agreement was executed for the amount of $50 million. Some of the covenants include NAVB maintaining a minimum EBITDA and revenue targets each year, otherwise the company will be obligated to raise a multiple of the shortfall in the form of equity or debts and place the funds in a blocked account. Another loan has been amended and now it allows the lender to convert any advances paid to NAVB into shares of common stock at a conversion price not lower than $2.53.[[tagnumber 1]] [[tagnumber 0]] [[tagnumber 1]] [[tagnumber 0]]Also, last month NAVB exchanged its outstanding convertible preferred stock for warrants. Though the total amount of new shares issuable stays the same at around 14 million, the purchase price of the warrants seems way too low at $0.01 for a share.[[tagnumber 1]] [[tagnumber 20]] [[tagnumber 1]]